Vol 9 Issue 4

Download PDF

Featuring

Issue Spotlight: Gene delivery platform evolution part 1: viral
Optimizing materials & consumables sourcing strategy through scale-up/-out 2023
Other articles
Webinars

Gene delivery platform evolution part 1: viral

Guest Editor:

Aravind Asokan, Professor in Surgery, Director of Gene Therapy, Professor of Biomedical Engineering, Professor of Molecular Genetics and Microbiology, at Duke University School of Medicine

CELL AND GENE THERAPY INSIGHTS

May 2023 Issue

Vol 9 Issue 4

Featuring

SPOTLIGHT

Gene delivery platform evolution part 1: viral

Foreword

Viral gene delivery platform evolution

Expert Insight

Fine tuning AAV: machine learning the capsid

Commentary

Unraveling the origins of human adeno-associated virus 5

Interview

Utilizing AI to drive AAV-based gene delivery to the CNS

At the cutting edge of AAV capsid engineering

Assessing recent milestones in AAV capsid discovery & development for CNS applications

Leveraging derisked AAV vector development & delivery approaches to enhance speed to market for rare disease gene therapies

Viewpoint

Harnessing the untapped potential of commensal viruses in genetic medicine

Supply Chain FOCUS

Optimizing materials & consumables sourcing strategy through scale-up/-out 2023

Interview

Quantifying manufacturing uncertainty and developing digital tools for supply chain optimization

Expert Roundtable

Cell culture in immune cell therapies: do more with less

FastFacts

Navigating the gene & cell therapy regulatory landscape: when, why and how to deploy GMP gene editing materials

Journal articles

Innovator Insight

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Expert Roundtable

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

FastFacts

Simple analytical tools for detection of impurities in biologics produced using the Sf-baculovirus platform

Designing viral vector clearance studies for CGT products according to ICH Q5A (R2): part 1

Designing viral clearance studies for CGT products according to ICH Q5A (R2): part 2

Webinars

Customize cell culture reagents and drive sustainability in your development: Make media and buffers your competitive advantage

Commercializing cell and gene therapies: Navigating complex commercial readiness hurdles for a successful product launch

Exploring novel approaches for AAV analysis

Flow cytometric assays for CAR T cell manufacturing and post-infusion monitoring

Leveraging the experience of cord blood banking in the development of cellular therapies